Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
← catalyst calendarNCT06548542 · readout ≤ 1,261 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
540estimated
Sites
255
Countries
Austria, Belgium, Bulgaria +30
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-04 | actual | When the study began enrolling |
| Primary completion | Jan 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Interventions
- Drug: Risankizumab
- Drug: Lutikizumab
- Drug: Trosunilimab
- Drug: Risankizumab
- Drug: Trosunilimab
- Drug: ABBV-8736
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants who Achieve Endoscopic Remission
measured Week 12
Number of Participants with Adverse Events (AEs)
measured Up to approximately 96 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed